The global assisted reproductive technology market size accounted for USD 31.61 billion in 2024, grew to USD 34.71 billion in 2025 and is predicted to surpass around USD 80.51 billion by 2034, representing a healthy CAGR of 9.80% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Assisted Reproductive Technology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Assisted Reproductive Technology Market, by Product, 2024-2034
8.1.1. Instrument
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Accessory & Disposable
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Reagents & media
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Assisted Reproductive Technology Market, by Technology, 2024-2034
9.1.1. In-Vitro Fertilization (IVF)
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Artificial Insemination
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Assisted Reproductive Technology Market, by Diagnosis, 2024-2034
10.1.1. Ovulation Testing
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Hysterosalpingography
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. Assisted Reproductive Technology Market, by End-User, 2024-2034
11.1.1. Ambulatory surgical centers
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Hospitals
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Clinics
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Diagnostic centers
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Gynecology Centers
11.1.5.1. Market Revenue and Forecast (2021-2034)
11.1.6. Feminist Health Centers
11.1.6.1. Market Revenue and Forecast (2021-2034)
11.1.7. IVF Centers
11.1.7.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.1.4. Market Revenue and Forecast, by End-User (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.2.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.3.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.4.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Diagnosis (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End-User (2021-2034)
13.1. Vitrolife AB
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific, Inc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. The Cooper Companies, Inc (Cooper Surgical Inc.)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Progyny Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Oxford Gene Technology
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Millendo Therapeutics, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck KGaA (EMD Serono, Inc)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Genera Biomedx
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Fujifilm Holdings Corporation (Irvine Scientific Sales Company)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Cook Medical Inc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample